^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    TC-A101

    i
    Other names: TC-A101, anti-ALPP CAR-T cells, retroviral vector-transduced autologous T cells to express anti-ALPP CARs, TCA101, TC A101
    Company:
    TCRCure, Xinqiao Hospital
    Drug class:
    ALPP-targeted CAR-T immunotherapy
    Related drugs:
    4ms
    Engineered T-cell Therapy for Patients With ALPP-Positive Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=24, Recruiting, TCRCure Biopharma Ltd.
    New P1 trial
    |
    cyclophosphamide • fludarabine IV • TC-A101
    1year
    Anti-ALPP CAR-T Cells Immunotherapy for Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=20, Recruiting, Xinqiao Hospital of Chongqing | Suspended --> Recruiting
    Enrollment open • CAR T-Cell Therapy • Metastases
    |
    MSLN (Mesothelin)
    |
    MSLN positive
    |
    cyclophosphamide • TC-A101
    1year
    Anti-ALPP CAR-T Cells Immunotherapy for Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=20, Suspended, Xinqiao Hospital of Chongqing | Recruiting --> Suspended
    Trial suspension
    |
    MSLN (Mesothelin)
    |
    MSLN positive
    |
    cyclophosphamide • TC-A101
    over1year
    Anti-ALPP CAR-T Cells Immunotherapy for Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=20, Recruiting, Xinqiao Hospital of Chongqing | Not yet recruiting --> Recruiting | Trial completion date: Dec 2023 --> May 2025 | Trial primary completion date: Dec 2022 --> Dec 2024
    Enrollment open • Trial completion date • Trial primary completion date • CAR T-Cell Therapy • Metastases
    |
    MSLN (Mesothelin)
    |
    cyclophosphamide • TC-A101